The NIVA|HF investigational algorithm uses proprietary venous waveform technology from VoluMetrix to assess otherwise hard-to-obtain cardiovascular metrics. According to study authors, ‘This non-invasive measurement has potential for … prevention of hospital admission in heart failure patients.’ NASHVILLE, Tenn., Nov. 04, 2021 (GLOBE NEWSWIRE) — VoluMetrix, a Nashville-based biotech startup dedicated […]
Other News
Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update
Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones. “We are on track for submission around year-end of our […]
Cytokinetics Reports Third Quarter 2021 Financial Results
Submission of NDA for Omecamtiv Mecarbil on Track to Occur in Q4 2021 Start-Up Activities Underway for SEQUOIA-HCM Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2022 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third […]
Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update
– Increased adoption of generic Treprostinil Injection by patients, physicians and payers – Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities – Anticipate FDA action on LIQ861 near PDUFA goal date of November 7, 2021 MORRISVILLE, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) […]
AtriCure Reports Third Quarter 2021 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. “Our results were driven by strong growth across key product lines, including the addition of new Cryo Nerve Block and Hybrid AF™ Therapy […]
ReCor Medical Reports Latest Data from Landmark Renal Denervation Clinical Trials at TCT Annual Meeting
RADIANCE-HTN TRIO and SOLO trial updates demonstrate the durability of blood pressure lowering effects of the Paradise Ultrasound Renal Denervation System in a broad spectrum of patients with hypertension. PALO ALTO, Calif.–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a fully owned subsidiary of Otsuka Holdings Co., Ltd., and […]
TARA Biosystems Partners with Scipher Medicine®
Scipher to use proprietary patient molecular data analyzed by its SpectraTM platform to identify novel drug targets. TARA Biosystems to progress selected targets in its BiowireTM II drug discovery platform for cardiac laminopathies. Partnership set to reduce target discovery and validation from years down to months. NEW YORK & WALTHAM, […]
iRhythm Technologies Comments on Centers for Medicare and Medicaid Services 2022 Medicare Physician Fee Schedule Final Rule
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions company focused on the advancement of cardiac care, today commented on the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule. The Final […]
Zynex Announces 2021 Third Quarter Earnings
ENGLEWOOD, Colo., Nov. 2, 2021 /PRNewswire/ — 2021 Third Quarter Revenue increased 74% year over year to $34.8 million Orders increased 70% Record net income of $6.1 million; Diluted EPS $0.17 Adjusted EBITDA $9.3 million Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, […]
Ionis reports third quarter 2021 financial results and recent business achievements
Olezarsen (IONIS-APOCIII-L Rx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-L Rx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track for year-end Tofersen Phase 3 VALOR study missed primary endpoint; signs of reduced disease progression observed across multiple secondary and […]



